Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), please find ....

June 23, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Limited BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Dear Sir/Madam, Sub: Annual Report for the Financial Year ended March 31, 2026 This is further to our letter dated May 12, 2026, wherein the Company informed that the 41st Annual General Meeting (“41st AGM”) of the Company is scheduled to be held on Wednesday, July 15, 2026, through Video Conference/Other Audio-Visual Means, in accordance, with the relevant circulars issued by Ministry of Corporate Affairs (‘MCA’) and Securities and Exchange Board of India (‘SEBI’). Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), please find enclosed the Notice convening the 41st AGM and the Annual Report of the Company for the financial year 2025-2026. In accordance with the aforesaid circulars, the Notice of the 41st AGM and the Annual Report of the Company for the financial year 2025-2026 are sent through electronic mode to all those members of the Company whose email addresses are registered with the Company/Registrar and Share Transfer Agent/ Depository Participant(s). The Notice of the 41st AGM and Annual Report for the financial year 2025-2026 is available on the website of the Company at https://www.blissgvs.com/annual-reports . Further, in accordance with Regulation 42 of the SEBI Listing Regulations, kindly note that the Company has fixed Wednesday, July 08, 2026, as the Record Date for determining the entitlement of members to the final dividend for the financial year ended March 31, 2026. If the final dividend, as recommended by the Board of Directors, is approved at the 41st AGM by the shareholders, payment of such dividend, subject to deduction of tax at source, will be made on or before Friday, August 14, 2026. This is for your information and records. Thanking you. Yours faithfully, For Bliss GVS Pharma Limited Aditi Bhatt Company Secretary and Compliance Officer Encl: As above Capability. Capacity. Consistency. Bliss GVS Pharma Limited 41st Annual Report 2025-26 Driven by purpose and powered by people, Bliss GVS CONTENTS Pharma continues to extend its global footprint, delivering innovative, reliable, and affordable healthcare solutions. Scan the QR code to know Our journey is defined by expertise, robust infrastructure, more about us and an unswerving commitment to excellence, laying the foundation for products that make a meaningful impact on Corporate patients’ lives worldwide. Overview 02 _ About Us 04 _ Managing Director and CEO Message Building on this foundation, Capability Our Capacity enables us to scale Consistency underscores our 06 _ Our Journey is reflected in our steadfast commitment operations efficiently and meet the unwavering reliability. Since our 08 _ Geographical Presence to quality and efficacy. With our generic growing needs of healthcare markets establishment, we have maintained 10 _ Our Offerings formulations successfully passing globally. Advanced manufacturing excellence across therapeutic segments bioequivalence studies, we validate facilities, structured procedures and and dosage forms, earning trust in over 12 _ Financial Highlights both the safety and effectiveness of policies aligned with international 60 countries. Recognised globally for our 14 _ Value Creation Model our products, reinforcing their ongoing pharmaceutical standards allow us to expertise in suppositories and pessaries, Read our Annual Report online at 16 _ Operational Excellence contribution to patient care. deliver consistent results. Complementing we continuously uphold the highest 18 _ R&D https://blissgvs.com/investors/ this, our DSIR-certified R&D Centre in standards of quality, sustainability and financials/annual-reports-2/ 20 _ Supply Chain Mumbai, equipped with state-of-the-art environmental responsibility, delivering 22 _ Stakeholder Engagement technology and operating under Good healthcare solutions that patients and 24 _ Human Capital Laboratory Practices, empowers us to partners can confidently rely on. Disclaimer 28 _ ESG innovate and introduce new solutions. The contents of Annual Report with regard to the 31 _ Board of Directors and Committees business section are for information purposes only and it contains general background information about 32 _ Corporate Information the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent development, information, or events, or otherwise. This Annual Report comprises information given in summary form and does not purport to be Statutory complete. The contents of Annual Report should not Section be considered as a recommendation to any investor Together, these three pillars— to purchase the equity shares of the Company. These contents include statements that are, or may 33 _ Notice be deemed to be, “forward-looking statements”. By 45 _ Board’s Report Capability, Capacity and their nature, forward-looking statements involve risks and uncertainties because they relate to events, and 64 _ Management Discussion and Analysis Report depend on circumstances, that may or may not occur 74 _ Corporate Governance Report Consistency—form the backbone of in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the our journey. They drive innovation, Company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No enable sustainable growth and representation, warranty or undertaking, express Financial or implied, is made or assurance given that such ensure that every product we deliver statements, views, projections or forecasts, if any, Section are correct or that the objectives of the Company will be achieved. The past performance is not indicative Standalone creates a tangible, lasting impact on of future results. This document has not been and will not be reviewed or approved by the statutory 101 _ Independent Auditor’s Report auditors or a regulatory authority in India or by any global healthcare. stock exchange in India. To ensure conciseness 112 _ Standalone Financial Statements and avoid repetition, certain information relevant Consolidated to multiple sections of this Annual Report has been 164 _ Independent Auditor’s Report disclosed only in the most appropriate section. Stakeholders are advised to refer to the complete 172 _ Consolidated Financial Statements Report for a comprehensive understanding of all disclosures made. Bliss GVS Pharma Limited Corporate Overview Capability. 41st Annual Report 2025-26 Statutory Section Financial Section Capacity. Consistency. About Us Innovating for a Vision Our vision is to be a consistent innovator Healthier Tomorrow and leading provider of pharmaceutical formulations which improve accessibility and quality of life globally. We are a leading global manufacturer of suppositories and pessaries, delivering dependable solutions supported by decades of expertise, world-class manufacturing and an extensive international presence. Values Built on a strong foundation, we have Key highlights consistently strengthened our capabilities through deep scientific insight and robust ₹ 9,271 6 Integrity Performance Customer Pursuit of R&D. By bolstering manufacturing prowess Mn Trust Excellence and expanding geographic footprint, we Revenue Total Manufacturing units adapt to the evolving needs of diverse markets. We deliver innovative, patient- centric solutions across a range of dosage ₹ 1,615 60+ Mn Countries forms and therapeutic categories. Our commitment to [Showing first 8,000 characters — download PDF for full document]